There was no significant change in the γGT levels .
Significant differences were not found .
CONCLUSION Silymarin minimally reduced , but without clinical relevance , the serum levels of ALT and AST .
AIM To evaluate the effect of silymarin on the serum levels of alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) and gamma glutamyl transpeptidase ( γGT ) in patients with liver diseases .
Serum Oxidative Stress Markers and Lipidomic Profile to Detect NASH Patients Responsive to an Antioxidant Treatment: A Pilot Study
Liver steatosis can evolve to steatohepatitis ( NASH ) through a series of biochemical steps related to oxidative stress in hepatocytes . Antioxidants , such as silybin , have been proposed as a treatment of patients with nonalcoholic fatty liver disease ( NAFLD ) and NASH . In this study , we evaluated , in patients with histologically documented NASH , the oxidant/antioxidant status and lipid “ fingerprint ” in the serum of NASH patients , both in basal conditions and after 12 months of treatment with silybin-based food integrator Realsil ( RA ) . The oxidant/antioxidant status analysis showed the presence of a group of patients with higher basal severity of disease ( NAS scores 4.67 ± 2.5 ) and a second group corresponding to borderline NASH ( NAS scores = 3.8 ± 1.5 ) . The chronic treatment with RA  changed the NAS score in both groups that reached the statistical significance only in group 2 , in which there was also a significant decrease of serum lipid peroxidation . The lipidomic profile showed a lipid composition similar to that of healthy subjects with a restoration of the values of free cholesterol , lysoPC , SM , and PC only in group 2 of patients after treatment with RA . Conclusion . These data suggest that lipidomic and /or oxidative status of serum from patients with NASH could be useful as prognostic markers of response to an antioxidant treatment
There was no significant change in the γGT levels .
Significant differences were not found .
CONCLUSION Silymarin minimally reduced , but without clinical relevance , the serum levels of ALT and AST .
AIM To evaluate the effect of silymarin on the serum levels of alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) and gamma glutamyl transpeptidase ( γGT ) in patients with liver diseases .